Status unknownNCT02695979Updated Mar 1, 2018

Changes of Macrophage Migration Inhibitory Factor During Orthotopic Liver Transplantation

An observational study in Evidence of Liver Transplantation, sponsored by Medical University of Vienna. Status unknown at 1 site in Austria. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-03-01.

Sponsored by Medical University of Vienna · Observational

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Active, not recruiting — may be out of date.

Study type: Observational
Model: Cohort
Time perspective: Prospective
Enrollment: 100
Ages: 18 Years to 70 Years
Sex: All

Study summary

Collecting blood, graft liver effluent and urine samples from patients undergoing orthotopic liver transplantation.

Read the detailed description

Aims are to measure Macrophage Migration Inhibitory Factor, Macrophage Migration Inhibitory Factor II and its' soluble receptor CD74 in serum, liver graft effluent and urine in and evaluate MIF's role in hepatic ischemia/reperfusion injury, postoperative graft function and kidney function.

Conditions studied

Evidence of Liver Transplantation

In context

Lead sponsor

Medical University of Vienna is the lead sponsor of 1,105 studies on the registry; 182 are open to participants now.

Browse Medical University of Vienna studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 70 Years
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Probability sample

Study population

Patients undergoing orthotopic liver transplantation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

End stage liver disease, chronic liver failure, orthotopic liver transplantation

Exclusion criteria

Exclusion Criteria:

Combined transplantations (liver plus kidney or lung), age under 18 y, acute liver failure

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 100 participants (actual)
Patient registry: No
Biospecimen retention: Samples without dna

Groups and cohorts

Patients undergoing OLT
Patients aged 18-70 with end-stage liver disease undergoing orthotopic liver transplantation (OLT).

What researchers measure

Primary outcomes

Macrophage Migration Inhibitory Factor in human serum, liver graft effluent and urine
Time frame: 24 months

Other outcomes

Acute kidney injury, outcome
Acute kidney injury, outcome
Time frame: 48 months

Study locations

1 site

Medical University Vienna
Vienna, 1090, Austria

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Mar 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT02695979
Lead sponsor: Medical University of Vienna
Responsible party: Dr. Joanna Stefaniak (Dr.med., Medical University of Vienna) — Principal investigator
First posted: Mar 2, 2016
Start date: Aug 2014
Primary completion: Sep 2018 (estimated)
Completion: Aug 2019 (estimated)
Last update: Mar 1, 2018

Study contacts

Peter Faybik, Prof

study chair · Medical University Vienna, Department of Anesthesia, General Intensive Care and Pain Management

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Medical University of Vienna →

Start the discussion